Bacteremia caused by Brevundimonas species at a tertiary care hospital in Taiwan, 2000–2010
- 553 Downloads
We investigated clinical and microbiological characteristics of 30 patients with Brevundimonas bacteremia treated at a tertiary care hospital in Taiwan during 2000–2010. All the 30 bacteria isolates were confirmed to the species level by 16S rRNA sequencing analysis. Minimum inhibitory concentrations (MICs) of 11 antimicrobial agents against these isolates were determined by the agar dilution method. Seventeen (57%) patients had underlying malignancy, 12 (40%) had undergone central catheter placement, and 13 (43%) had received chemotherapy within the previous three months. Eight (27%) patients had community-acquired bacteremia and the remaining 22 patients (73%) had healthcare-associated bacteremia. The overall 14-day and 30-day mortality rates were 13% and 17%, respectively. Among the 30 isolates, B. vesicularis constituted most commonly (n = 22, 63%), followed by B. nasdae (n = 5) and B. diminuta (n = 3). All isolates were susceptible to piperacillin-tazobactam and amikacin, while all were resistant to ciprofloxacin and colistin. Tigecycline (MICs at which 90% of isolates are inhibited [MIC90] was 0.12 mg/L) and doripenem (MIC90 of 1 mg/L) both possessed good in vitro activities. In conclusions, Brevundimonas should be considered a pathogen that can cause bacteremia in immunocompromised hosts. Piperacillin-tazobactam, amikacin, doripenem, and tigecycline exhibit good in vitro activities against these ciprofloxacin- and colistin-resistant Brevundimonas species.
KeywordsInfective Endocarditis Colistin Cefepime Tigecycline Ertapenem
All authors declare no conflicts of interest.
- 1.Segers P, Vancanneyt M, Pot B, Torck U, Hoste B, Dewettinck D et al (1994) Classification of Pseudomonas diminuta Leifson and Hugh 1954 and Pseudomonas vesicularis Busing, Doll, and Freytag 1953 in Brevundimonas gen. nov. as Brevundimonas diminuta comb. nov. and Brevundimonas vesicularis comb. nov., respectively. Int J Syst Bacteriol 44:499–510PubMedCrossRefGoogle Scholar
- 2.Otto LA, Deboo BS, Capers EL, Pickett MJ (1987) Pseudomonas vesicularis from cervical specimens. J Clin Microbiol 7:341–345Google Scholar
- 9.Clinical Laboratory and Standard Institute (2010) Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20Google Scholar
- 12.Lee MR, Huang YT, Liao CH, Lai CC, Lee PI, Hsueh PR (2010) Bacteraemia caused by Weissella confusa at a university hospital in Taiwan, 1997–2007. Clin Microbiol Infect [Epub ahead of print]Google Scholar
- 24.Clark WA, Hollis DG, Weaver RE, Riley P (1984) Identification of unusual pathogenic gram-negative aerobic and facultatively anaerobic bacteria. In: US Department of Health and Human Services CDC (Ed), Atlanta, GA, USAGoogle Scholar